{"id":"afm-13","safety":{"commonSideEffects":[{"rate":"10%","effect":"Cytokine release syndrome"},{"rate":"20%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4297874","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"AFM 13 binds to CD30 on the surface of tumor cells and CD16A on NK cells, leading to the activation and redirection of NK cells to specifically target and kill CD30-positive tumor cells, thereby enhancing the immune response against these malignancies.","oneSentence":"AFM 13 is a tetravalent bispecific antibody construct that targets CD30 on tumor cells and CD16A on natural killer (NK) cells, enhancing NK cell-mediated cytotoxicity against CD30-positive tumors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T05:51:15.958Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hodgkin lymphoma"},{"name":"anaplastic large cell lymphoma"}]},"trialDetails":[{"nctId":"NCT01221571","phase":"PHASE1","title":"A Study to Assess AFM13 in Patients With Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Affimed GmbH","startDate":"2010-10","conditions":"Hodgkin Lymphoma","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AFM 13","genericName":"AFM 13","companyName":"Affimed GmbH","companyId":"affimed-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AFM 13 is a tetravalent bispecific antibody construct that targets CD30 on tumor cells and CD16A on natural killer (NK) cells, enhancing NK cell-mediated cytotoxicity against CD30-positive tumors. Used for Hodgkin lymphoma, anaplastic large cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}